Active substance
Results for the substance efgartigimod alfa
3 results
About this active substance
Efgartigimod alfa is a medication used for the treatment of generalized myasthenia gravis in adult patients with antibodies against the acetylcholine receptor. It works by reducing levels of pathogenic immunoglobulin G (IgG), thereby alleviating disease symptoms.
The medication is administered via intravenous infusion, usually once a week for four weeks. It is effective in improving muscle strength and quality of life for patients.
Side effects may include upper respiratory tract infections, headache, fatigue, and infusion site reactions. Close monitoring is essential to manage potential complications.
Consult your doctor to discuss the benefits and risks of treatment with Efgartigimod alfa. This medication must be administered under the supervision of a specialist.
The medication is administered via intravenous infusion, usually once a week for four weeks. It is effective in improving muscle strength and quality of life for patients.
Side effects may include upper respiratory tract infections, headache, fatigue, and infusion site reactions. Close monitoring is essential to manage potential complications.
Consult your doctor to discuss the benefits and risks of treatment with Efgartigimod alfa. This medication must be administered under the supervision of a specialist.
-
-
VYVGART 1000mg 200mg/ml solution for injection in pre-filled syringe ARGENX BV ORIGINAL MEDICINE
-
VYVGART 1000mg 180mg/ml solution for injection ARGENX BV ORIGINAL MEDICINE